Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Development of pulmonary endovascular metastases following vertebroplasty: case report.

Mercer J, Lam ACL, Smith R, Fallah-Rad N, Kavanagh J.

J Neurosurg Spine. 2019 Nov 29:1-4. doi: 10.3171/2019.9.SPINE19915. [Epub ahead of print]

PMID:
31783355
2.

Treatment and resource recovery options for first and second generation bioethanol spentwash - A review.

Cooper J, Kavanagh J, Razmjou A, Chen V, Leslie G.

Chemosphere. 2019 Sep 25;241:124975. doi: 10.1016/j.chemosphere.2019.124975. [Epub ahead of print] Review.

PMID:
31610460
3.

Metabolic Engineering of the MEP Pathway in Bacillus subtilis for Increased Biosynthesis of Menaquinone-7.

Ma Y, McClure DD, Somerville MV, Proschogo NW, Dehghani F, Kavanagh JM, Coleman NV.

ACS Synth Biol. 2019 Jul 19;8(7):1620-1630. doi: 10.1021/acssynbio.9b00077. Epub 2019 Jun 28.

PMID:
31250633
4.

Characterisation of dissolved organic matter in fermentation industry effluents and comparison with model compounds.

Cooper J, Antony A, Luiz A, Kavanagh J, Razmjou A, Chen V, Leslie G.

Chemosphere. 2019 Nov;234:630-639. doi: 10.1016/j.chemosphere.2019.05.272. Epub 2019 May 30.

PMID:
31229724
5.

CT-guided Lung Biopsy: Effect of Biopsy-side Down Position on Pneumothorax and Chest Tube Placement.

Drumm O, Joyce EA, de Blacam C, Gleeson T, Kavanagh J, McCarthy E, McDermott R, Beddy P.

Radiology. 2019 Jul;292(1):190-196. doi: 10.1148/radiol.2019182321. Epub 2019 May 14.

PMID:
31084480
6.

Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts.

Aggarwal R, Lam ACL, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, Liu G, Kavanagh J.

J Thorac Oncol. 2019 Jun;14(6):1003-1011. doi: 10.1016/j.jtho.2019.01.031. Epub 2019 Feb 13.

PMID:
30771523
7.

CT-guided Microcoil Pulmonary Nodule Localization prior to Video-assisted Thoracoscopic Surgery: Diagnostic Utility and Recurrence-Free Survival.

Rodrigues JCL, Pierre AF, Hanneman K, Cabanero M, Kavanagh J, Waddell TK, Chung TB, Pakkal M, Keshavjee S, Cypel M, Yasufuku K, Nguyen ET.

Radiology. 2019 Apr;291(1):214-222. doi: 10.1148/radiol.2019181674. Epub 2019 Feb 5.

PMID:
30720402
8.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT.

Eur J Cancer. 2019 Mar;109:28-35. doi: 10.1016/j.ejca.2018.11.030. Epub 2019 Jan 24.

PMID:
30685684
9.

Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.

Soldera SV, Kavanagh J, Pintilie M, Leighl NB, de Perrot M, Cho J, Hope A, Feld R, Bradbury PA.

Oncologist. 2019 Jul;24(7):e510-e517. doi: 10.1634/theoncologist.2018-0501. Epub 2018 Nov 26.

PMID:
30478189
10.

Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening.

Kavanagh J, Liu G, Menezes R, O'Kane GM, McGregor M, Tsao M, Shepherd FA, Schmidt H.

Radiology. 2018 Oct;289(1):218-224. doi: 10.1148/radiol.2018180053. Epub 2018 Jul 10.

PMID:
29989522
11.

A potential biotechnological process for the sustainable production of vitamin K1.

Tarento TDC, McClure DD, Talbot AM, Regtop HL, Biffin JR, Valtchev P, Dehghani F, Kavanagh JM.

Crit Rev Biotechnol. 2018 May 24:1-19. doi: 10.1080/07388551.2018.1474168. [Epub ahead of print]

PMID:
29793354
12.

Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.

Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK.

Front Oncol. 2018 Feb 9;8:9. doi: 10.3389/fonc.2018.00009. eCollection 2018.

13.

Utility of transthoracic needle biopsy after lung transplantation.

Kavanagh J, Siemienowicz M, Keshavjee S, Rogalla P, Singer L, Kandel S.

Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13168. Epub 2018 Jan 29.

PMID:
29194758
14.

Protective Capnothorax During Transthoracic Needle Biopsy.

Kavanagh J, Siemienowicz ML, Lyen S, Kandel S, Rogalla P.

Cardiovasc Intervent Radiol. 2017 Apr;40(4):603-608. doi: 10.1007/s00270-016-1549-1. Epub 2016 Dec 27.

PMID:
28028576
15.

Ultrasound-guided fine needle aspiration of thyroid nodules: factors affecting diagnostic outcomes and confounding variables.

Kavanagh J, McVeigh N, McCarthy E, Bennett K, Beddy P.

Acta Radiol. 2017 Mar;58(3):301-306. doi: 10.1177/0284185116654331. Epub 2016 Jul 20.

PMID:
27329396
16.

Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters.

Logan C, O'Connell N, Kavanagh J, McEniff N, Ryan M, Guiney M, Seery O, O'Donnell J, Ryan K, White B.

Thrombosis. 2016;2016:6538456. doi: 10.1155/2016/6538456. Epub 2016 Mar 27.

17.

Simulation and prediction of protein production in fed-batch E. coli cultures: An engineering approach.

Calleja D, Kavanagh J, de Mas C, López-Santín J.

Biotechnol Bioeng. 2016 Apr;113(4):772-82. doi: 10.1002/bit.25842. Epub 2015 Oct 18.

PMID:
26416399
18.

Fluoroscopically guided transurethral removal and/or replacement of ureteric stents in women.

McCarthy E, Kavanagh J, McKernan S, O'Mahony N, McEniff N, Ryan JM, Guiney M.

Acta Radiol. 2015 May;56(5):635-40. doi: 10.1177/0284185114533246. Epub 2014 May 2.

PMID:
24792357
19.

High-sensitivity troponin as an outcome predictor in acute medical admissions.

Courtney D, Conway R, Kavanagh J, O'Riordan D, Silke B.

Postgrad Med J. 2014 Jun;90(1064):311-6. doi: 10.1136/postgradmedj-2013-132325. Epub 2014 Apr 2.

PMID:
24696522
20.

Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases.

Callegaro-Filho D, Kavanagh JJ, Nick AM, Ramirez PT, Schmeler KM.

Case Rep Oncol. 2014 Jan 31;7(1):97-101. doi: 10.1159/000358916. eCollection 2014 Jan.

21.

Designing of an intensification process for biosynthesis and recovery of menaquinone-7.

Berenjian A, Mahanama R, Talbot A, Regtop H, Kavanagh J, Dehghani F.

Appl Biochem Biotechnol. 2014 Feb;172(3):1347-57. doi: 10.1007/s12010-013-0602-7. Epub 2013 Oct 31.

PMID:
24173914
22.

Vitamin K series: current status and future prospects.

Berenjian A, Mahanama R, Kavanagh J, Dehghani F.

Crit Rev Biotechnol. 2015 Jun;35(2):199-208. doi: 10.3109/07388551.2013.832142. Epub 2013 Sep 18. Review.

PMID:
24044610
23.

Transseptal transcatheter coil embolization of a symptomatic pulmonary arteriovenous aneurysm in a patient with hereditary hemorrhagic telangiectasia.

Joyce EA, Kavanagh J, Foley B, O'Connell F, McEniff N.

J Vasc Interv Radiol. 2013 Apr;24(4):601-3. doi: 10.1016/j.jvir.2013.01.002.

PMID:
23522164
24.

Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.

Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK.

Front Oncol. 2013 Mar 20;3:58. doi: 10.3389/fonc.2013.00058. eCollection 2013. Erratum in: Front Oncol. 2018 Feb 09;8:9.

25.

Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.

Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W.

Cancer Biol Ther. 2012 Sep;13(11):1034-41. doi: 10.4161/cbt.21045. Epub 2012 Aug 16.

26.

Effect of biofilm formation by Bacillus subtilis natto on menaquinone-7 biosynthesis.

Berenjian A, Chan NL, Mahanama R, Talbot A, Regtop H, Kavanagh J, Dehghani F.

Mol Biotechnol. 2013 Jun;54(2):371-8. doi: 10.1007/s12033-012-9576-x.

PMID:
22740166
27.

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.

Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB.

Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6.

28.

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M.

Gynecol Oncol. 2012 Jun;125(3):661-6. doi: 10.1016/j.ygyno.2012.02.037. Epub 2012 Mar 6.

29.

Efficient media for high menaquinone-7 production: response surface methodology approach.

Berenjian A, Mahanama R, Talbot A, Biffin R, Regtop H, Valtchev P, Kavanagh J, Dehghani F.

N Biotechnol. 2011 Oct;28(6):665-72. doi: 10.1016/j.nbt.2011.07.007. Epub 2011 Aug 3.

PMID:
21839866
30.

Adjuvant chemotherapy for endometrial cancer.

Tangjitgamol S, See HT, Kavanagh J.

Int J Gynecol Cancer. 2011 Jul;21(5):885-95. doi: 10.1097/IGC.0b013e3182169239. Review.

PMID:
21697679
31.

Techno-economic implications of improved high gravity corn mash fermentation.

Kollaras A, Kavanagh JM, Bell GL, Purkovic D, Mandarakas S, Arcenal P, Ng WS, Routledge KS, Selwood DH, Koutouridis P, Paras FE, Milic P, Tirado-Escobar ES, Moore MJ, Bell PJ, Attfield PV.

Bioresour Technol. 2011 Aug;102(16):7521-5. doi: 10.1016/j.biortech.2011.04.094. Epub 2011 May 1.

PMID:
21632242
32.

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr.

Cancer. 2011 Apr 15;117(8):1661-9. doi: 10.1002/cncr.25701. Epub 2010 Nov 8.

33.

Targeted therapies for rare gynaecological cancers.

Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ.

Lancet Oncol. 2010 Jul;11(7):685-93. doi: 10.1016/S1470-2045(09)70368-7. Epub 2010 Mar 31. Review.

PMID:
20362508
34.

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.

Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr.

J Hematol Oncol. 2010 Mar 11;3:9. doi: 10.1186/1756-8722-3-9.

35.

Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009.

Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, Ilancheran A, Lee KM, Lim SE, Chia YN, Domingo E, Kim YT, Lai CH, Dali AZ, Supakapongkul W, Wilailak S, Tay EH, Kavanagh J; Asian Oncology Summit.

Lancet Oncol. 2009 Nov;10(11):1119-27. doi: 10.1016/S1470-2045(09)70290-6. Review.

PMID:
19880066
36.

Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients.

Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist K.

Palliat Support Care. 2009 Sep;7(3):299-306. doi: 10.1017/S1478951509990228.

37.

Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer.

Zheng H, Hu W, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ.

Am J Obstet Gynecol. 2009 Oct;201(4):367.e1-6. doi: 10.1016/j.ajog.2009.05.021. Epub 2009 Jul 15.

PMID:
19608149
38.

Uterine Neoplasms. Clinical Practice Guidelines in Oncology.

Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR 3rd, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W Jr, Teng N.

J Natl Compr Canc Netw. 2009 May;7(5):498-531. Review. No abstract available.

PMID:
19460278
39.

Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients.

Jaishuen A, Jimenez C, Sirisabya N, Li Y, Zheng H, Hu W, Urbauer DL, Kavanagh JJ.

Int J Gynecol Cancer. 2009 Feb;19(2):178-85. doi: 10.1111/IGC.0b013e31819c0fd0.

PMID:
19395991
40.

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.

Gynecol Oncol. 2009 Jul;114(1):48-52. doi: 10.1016/j.ygyno.2009.03.001. Epub 2009 Apr 10.

PMID:
19361839
41.

Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.

Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S.

Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9. doi: 10.1016/j.ajog.2008.08.030. Epub 2008 Dec 25.

PMID:
19110234
42.

Update on aurora kinase inhibitors in gynecologic malignancies.

Tao X, Chon HS, Fu S, Kavanagh JJ, Hu W.

Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):162-77. Review.

43.

Chemotherapy for recurrent and metastatic cervical cancer.

Tao X, Hu W, Ramirez PT, Kavanagh JJ.

Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S67-71. doi: 10.1016/j.ygyno.2008.04.024. Epub 2008 Jun 3. Review.

PMID:
18533239
44.

Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.

Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ.

Pharm Res. 2008 Oct;25(10):2272-82. doi: 10.1007/s11095-008-9621-4. Epub 2008 May 29.

PMID:
18509599
45.

Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.

Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM.

Gynecol Oncol. 2008 Jul;110(1):56-9. doi: 10.1016/j.ygyno.2008.03.014. Epub 2008 May 5.

PMID:
18457865
46.

Cervical cancer.

Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR 3rd, Morgan M, Morgan RJ Jr, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W Jr, Teng N; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2008 Jan;6(1):14-36. No abstract available.

PMID:
18267056
47.

Hormone replacement therapy after treatment of endometrial cancer.

Tangjitgamol S, Manusirivithaya S, Hanprasertpong J, Kavanagh JJ.

Gynecol Obstet Invest. 2008;65(1):35-8. Epub 2008 Jan 15. Review.

PMID:
17687189
48.

Intraperitoneal chemotherapy in the treatment of ovarian cancer.

Kavanagh JJ.

J Surg Oncol. 2007 Dec 1;96(7):541-2. No abstract available.

PMID:
17654524
49.

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.

Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ.

Gynecol Oncol. 2007 Aug;106(2):375-80. Epub 2007 May 18.

PMID:
17512575
50.

Re: Samuel Pepys: a patient perspective of lithotomy in 17th century England.

Kavanagh JP.

J Urol. 2006 Oct;176(4 Pt 1):1687. No abstract available.

PMID:
16952714

Supplemental Content

Loading ...
Support Center